Efrat Venkert - Medigus External Director
| MDGSDelisted Stock | USD 2.36 0.15 6.79% |
Director
Ms. Efrat Venkert has served as External Director of Medigus Ltd since September 29, 2013. She is an attorney and licensed mediator. Prior to joing Medigus Ltd, she ran her own Law Office since 2013.
| Age | 46 |
| Tenure | 11 years |
| Phone | 972 73 370 4691 |
| Web | https://www.medigus.com |
Medigus Management Efficiency
The company has return on total asset (ROA) of (0.0663) % which means that it has lost $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3072) %, meaning that it created substantial loss on money invested by shareholders. Medigus' management efficiency ratios could be used to measure how well Medigus manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 10.13 M in liabilities with Debt to Equity (D/E) ratio of 0.27, which may suggest the company is not taking enough advantage from borrowing. Medigus Ltd ADR has a current ratio of 1.35, which is within standard range for the sector. Debt can assist Medigus until it has trouble settling it off, either with new capital or with free cash flow. So, Medigus' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medigus Ltd ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medigus to invest in growth at high rates of return. When we think about Medigus' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Nathaniel Woodson | Paragon 28 | 72 | |
| Eynat Tsafrir | BrainsWay | 51 | |
| Susan Knight | SurModics | 63 | |
| Susan Harnett | Paragon 28 | 57 | |
| Simon Pedder | Delcath Systems | 56 | |
| Laura Philips | Delcath Systems | 56 | |
| Orly Uri | BrainsWay | 59 | |
| David Kunin | Nortech Systems Incorporated | 54 | |
| Maria Sainz | IRIDEX | 52 | |
| Brian Dempsey | Paragon 28 | 36 | |
| Kristina Wright | Paragon 28 | 47 | |
| John Benson | SurModics | 69 | |
| Kenneth Ludlum | IRIDEX | 63 | |
| Samuel Navarro | STRATA Skin Sciences | ||
| Brian Larkin | Dynatronics | 48 | |
| Thomas Bowers | Paragon 28 | 70 | |
| David Stone | STRATA Skin Sciences | 58 | |
| Kathleen Iverson | Nortech Systems Incorporated | 58 | |
| Marco Taglietti | Delcath Systems | 57 | |
| Michael Mashaal | ReShape Lifesciences | 42 | |
| Lisa Heine | SurModics | 54 | |
Management Performance
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0663 |
Medigus Ltd ADR Leadership Team
Elected by the shareholders, the Medigus' board of directors comprises two types of representatives: Medigus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigus. The board's role is to monitor Medigus' management team and ensure that shareholders' interests are well served. Medigus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ilan Oren, Executive Officer | ||
| Efrat Venkert, External Director | ||
| Anat Naschitz, Director | ||
| Yaron Silberman, Chief Ltd | ||
| Ori Hershkovitz, External Director | ||
| Yair Rabinovitch, Director | ||
| Menashe Sonnenschein, Vice President - Operations | ||
| Gilad Mamlok, CFO | ||
| Christopher Rowland, CEO and Director | ||
| Eitan Machover, Independent Director | ||
| Minelu Sonnenschein, VP of Operations | ||
| Oded Yatzkan, Director of Fin. and Accounting and VP | ||
| Nissim Darvish, Chairman of the Board | ||
| Jeremy Starkweather, Director of Sales, Director of Marketing-United States | ||
| Yuval Yanai, Director | ||
| Aviel Shapira, Medical Director | ||
| Yair Rabinowitch, Director | ||
| Liron Carmel, Chief Officer | ||
| Erez Haimovitz, Director | ||
| Tali Dinar, Chief Officer | ||
| Doron Birger, Director | ||
| Tatyana Yossef, Controller | ||
| Yaron Zilberman, Vice President - Sales and Marketing |
Medigus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medigus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0663 | |||
| Profit Margin | (0.13) % | |||
| Operating Margin | (0.09) % | |||
| Current Valuation | 65.3 M | |||
| Shares Outstanding | 1.89 M | |||
| Shares Owned By Institutions | 0.29 % | |||
| Number Of Shares Shorted | 4.18 K | |||
| Price To Earning | 33.86 X | |||
| Price To Book | 0.15 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Medigus Ltd ADR information on this page should be used as a complementary analysis to other Medigus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Medigus Stock
If you are still planning to invest in Medigus Ltd ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigus' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stocks Directory Find actively traded stocks across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |